Vyleesi Post-Bariatric Surgery Use: What Clinicians and Patients Need to Know

What Is Bremelanotide and How Was It Approved?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist, primarily active at MC3R and MC4R in the central nervous system. It does not act on peripheral vascular receptors the way sildenafil does. The FDA approved it on June 21, 2019, under the brand name Vyleesi, specifically for generalized acquired HSDD in premenopausal women. 1

Mechanism of Action

The drug modulates dopaminergic and melanocortinergic pathways in the hypothalamus to increase sexual desire. 2 Unlike flibanserin (Addyi), which requires daily oral dosing and carries a black-box warning for alcohol interaction, bremelanotide is taken on an as-needed basis approximately 45 minutes before anticipated sexual activity. That on-demand profile makes it practically useful for women whose HSDD is situational or whose daily pill burden is already high, as is common after bariatric surgery.

The RECONNECT Trials

The key evidence base is the RECONNECT program, two Phase 3 randomized, placebo-controlled trials published in Obstetrics and Gynecology in 2019 (combined N=1,267). 2 Women receiving bremelanotide 1.75 mg subcutaneously showed statistically significant improvements versus placebo on two co-primary endpoints: the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 distress score. The mean increase in satisfying sexual events was 0.7 per month above placebo. That number appears modest, but the FSDS-DAO distress reduction was clinically meaningful for patients who reported significant baseline distress, which is the regulatory definition of HSDD. The authors concluded that "bremelanotide significantly improved sexual desire and decreased distress related to low sexual desire compared with placebo." 2

Why Bariatric Surgery Changes Sexual Function

Bariatric surgery does not simply reduce body weight. It reshapes the endocrine milieu in ways that directly affect sexual desire, arousal, and satisfaction.

Hormonal Reorganization After Weight Loss

Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy produce significant reductions in circulating estradiol within the first 12 months post-operatively, partly because adipose aromatase activity falls as fat mass decreases. 3 Sex hormone-binding globulin (SHBG) rises concurrently, reducing free testosterone. The net result is a transient state that resembles relative hypogonadism even in premenopausal women of reproductive age. A 2012 analysis in Obesity Surgery reported that SHBG increased by a mean of 58% at 12 months post-RYGB in premenopausal women. 3

Prolactin dynamics also shift. Dopamine tone increases after RYGB, which may modestly lower basal prolactin. But nutritional deficiencies in zinc and vitamin D, both highly prevalent post-bariatric, can independently impair hypothalamic-pituitary-gonadal axis function. 4

Psychosocial Factors and Body Image

Sexual desire is not purely neurochemical. Post-bariatric women frequently report improved body image and sexual confidence in the first 12 to 24 months after surgery, which may transiently reduce HSDD prevalence. 5 Beyond 24 months, particularly if weight regain occurs or if relationship dynamics remain strained, HSDD can re-emerge or persist. Clinicians should time HSDD evaluation to at least 6 months post-operatively, after acute post-surgical hormonal flux stabilizes.

Bremelanotide Pharmacokinetics in Post-Bariatric Patients

This section addresses the most clinically specific question: does bariatric surgery change how bremelanotide behaves in the body?

Subcutaneous Delivery Bypasses GI Anatomy

Bremelanotide is delivered via a prefilled auto-injector into the abdomen or thigh. Because the drug never enters the gastrointestinal tract, the anatomical changes from RYGB (bypassed duodenum and proximal jejunum) or sleeve gastrectomy (reduced gastric volume) have no direct effect on drug absorption. 6 This is a meaningful clinical advantage over oral medications whose pharmacokinetics are substantially disrupted in post-bariatric patients.

Body Composition Effects on Volume of Distribution

Bremelanotide's volume of distribution is approximately 22 liters, reflecting limited tissue binding. 6 As body fat decreases post-bariatric surgery, the ratio of drug concentration in lean versus adipose tissue shifts. For highly lipophilic drugs, this produces measurable changes in half-life. Bremelanotide is moderately lipophilic (log P approximately 1.0), so the effect is likely small but has not been studied specifically in post-bariatric cohorts. The half-life reported in the FDA prescribing information is approximately 2.7 hours across a weight range of 52 to 140 kg. 1 Patients at the lower end of that range after significant weight loss fall within the studied population.

Renal and Hepatic Clearance

Bremelanotide is cleared primarily through peptidase-mediated hydrolysis rather than hepatic CYP450 metabolism. 6 This matters for post-bariatric patients who may have pre-existing non-alcoholic fatty liver disease (NAFLD) in various stages of resolution. The drug does not require hepatic dose adjustment for mild-to-moderate hepatic impairment. Renal clearance accounts for a minority of elimination, and no dose adjustment is needed for eGFR <60 based on available data, though severe renal impairment (eGFR <30) has not been fully characterized. 1

Managing Nausea: The Dominant Clinical Challenge

Nausea occurred in 40.0% of bremelanotide-treated women in RECONNECT versus 1.4% with placebo. 2 Most episodes were mild to moderate and resolved within 2 hours. In post-bariatric patients, this creates an additive challenge.

Why Post-Bariatric Patients Are at Higher Risk

Post-bariatric patients have heightened GI sensitivity for multiple reasons. Reduced gastric volume increases gastric emptying speed. Altered GLP-1 and PYY secretion already produces nausea-like sensations after certain meals. Dumping syndrome, present in up to 20% of RYGB patients at 12 months, adds baseline nausea vulnerability. 7

The melanocortin MC4R receptor, which bremelanotide activates, is expressed in the area postrema (the brain's chemoreceptor trigger zone). That receptor-level mechanism is the likely reason nausea is the drug's most common adverse effect, and it cannot be fully mitigated by anti-nausea pretreatment. 8

Practical Mitigation Strategies

The RECONNECT investigators offered ondansetron 4 mg orally 30 minutes prior to dosing as a study-permitted rescue option. In a post-bariatric patient already managing multiple supplements, adding a prn antiemetic is feasible. Clinicians should also counsel patients to avoid using bremelanotide within 2 hours of a large meal, which is standard post-bariatric nutritional advice anyway. Starting with a test dose at a non-sexual occasion can help gauge individual nausea sensitivity before the drug is used in its intended context. Per the FDA prescribing information, a second dose should not be given within 24 hours. 1

Cardiovascular and Blood Pressure Considerations

Bremelanotide transiently increases mean arterial blood pressure by approximately 2 mmHg and reduces heart rate by approximately 4 to 5 bpm, lasting 8 to 12 hours after a single dose. 1 The drug is contraindicated in women with uncontrolled hypertension or known cardiovascular disease.

Post-Bariatric Cardiovascular Profile

Bariatric surgery markedly reduces blood pressure in hypertensive patients. The Swedish Obese Subjects study reported that 34% of bariatric patients who had hypertension at baseline achieved remission at 10 years. 9 Many post-bariatric patients are therefore no longer on antihypertensives and have well-controlled blood pressure, reducing the cardiovascular contraindication risk over time.

Clinicians should obtain a baseline blood pressure reading at the visit where bremelanotide is prescribed. If systolic blood pressure exceeds 130 mmHg at that visit, optimizing antihypertensive therapy before initiating bremelanotide is the appropriate sequence.

Drug Interactions Specific to Bariatric Pharmacotherapy

Naltrexone-Bupropion Interaction

Naltrexone-bupropion (Contrave) is FDA-approved for weight management and is sometimes continued post-bariatric surgery for weight maintenance. Naltrexone is an opioid receptor antagonist that also modulates melanocortin pathways. 10 Preclinical data suggest that opioid receptor blockade can reduce MC4R signaling efficiency. The clinical magnitude of this interaction has not been quantified in a dedicated trial, but the theoretical reduction in bremelanotide efficacy is biologically plausible. Prescribers combining these agents should document informed consent regarding uncertain combined efficacy.

GLP-1 Receptor Agonists

Semaglutide and liraglutide are increasingly used post-bariatric for weight maintenance. Neither drug uses CYP450 pathways. No pharmacokinetic interaction with bremelanotide has been identified. However, GLP-1 agonists independently cause nausea, particularly in the first 4 to 8 weeks of dose titration. 11 Concurrent use of bremelanotide during GLP-1 titration may produce additive nausea that is poorly tolerated. Timing bremelanotide initiation to after GLP-1 dose stabilization is a reasonable clinical approach.

Indomethacin and NSAIDs

The FDA prescribing information notes that bremelanotide may slow gastric emptying when co-administered with indomethacin, specifically observed as reduced indomethacin AUC. 1 Post-bariatric patients taking NSAIDs for joint pain (a common post-weight-loss musculoskeletal concern) should be counseled to separate dosing by at least 4 hours.

Hormonal Therapy Integration

Many post-bariatric women with HSDD are also candidates for testosterone therapy (off-label) or estradiol replacement if they are perimenopausal. The Endocrine Society's 2019 guidelines state that "testosterone therapy in women should be considered for the treatment of HSDD" and recommend a target total testosterone of 5 to 10 nmol/L (approximately the premenopausal physiologic range). 12

Bremelanotide and testosterone address distinct mechanisms. Testosterone supports tonic baseline desire and genital sensitivity through androgen receptor activation in peripheral tissue. Bremelanotide modulates acute central dopaminergic and melanocortinergic drive immediately before sexual activity. They are not redundant, and a post-bariatric patient with both low free testosterone and situational HSDD may benefit from both simultaneously. A sequential approach is also reasonable: optimize hormonal status first (6 to 12 weeks of testosterone), then reassess residual HSDD before adding bremelanotide.

The recommended pre-prescription workup for a post-bariatric patient with HSDD should include total and free testosterone, SHBG, estradiol, prolactin, TSH, and a validated distress instrument such as the FSDS-DAO. 13

Nutrient Deficiencies and Their Role in HSDD Post-Bariatric Surgery

Post-bariatric patients carry a substantial burden of micronutrient deficiency. Vitamin B12 deficiency affects up to 30% of RYGB patients at 1 year. Zinc deficiency affects 36 to 51% at 2 years. Both nutrients are co-factors in dopaminergic neurotransmission and steroidogenesis. 4

Vitamin D deficiency, present in over 50% of post-RYGB patients without supplementation, is associated with lower testosterone levels in women. 14 Correcting these deficiencies before attributing HSDD solely to a desire disorder addressable by bremelanotide is good clinical practice. A patient whose HSDD resolves with B12 repletion alone has been appropriately treated without adding a prescription drug.

Patient Selection and Contraindications in the Post-Bariatric Population

Not every post-bariatric woman with reduced sexual desire meets the diagnostic criteria for HSDD. The DSM-5 requires that the low desire cause marked distress and be present for at least 6 months. 15 Reduced desire in the first 6 months post-surgery, driven by fatigue, caloric restriction, and surgical recovery, does not qualify.

Absolute contraindications to bremelanotide in this population include:

• Uncontrolled hypertension (systolic >140 mmHg or diastolic >90 mmHg at time of prescribing)
• Known cardiovascular disease, including history of stroke or MI
• Hypersensitivity to bremelanotide or any component of the formulation

Relative cautions specific to post-bariatric patients include:

• Active dumping syndrome (additive nausea risk)
• GLP-1 agonist dose titration phase (additive nausea risk)
• Concurrent naltrexone use (uncertain efficacy reduction)
• Severe renal impairment (eGFR <30), inadequately studied

Monitoring After Initiation

The RECONNECT protocol used 8-week and 24-week assessment points. In clinical practice, a 6 to 8 week follow-up call is appropriate to review tolerability (particularly nausea frequency and severity), perceived efficacy on the patient's personal FSDS-DAO or similar scale, and blood pressure. 2

Women who do not report any benefit in satisfying sexual events or desire scores after 8 uses should have their diagnosis and hormonal status reassessed before continuing the prescription. The drug is not effective in all women with HSDD. The RECONNECT responder analysis showed that approximately 25% of treated women reported a clinically meaningful improvement versus 17% on placebo, an absolute response difference of roughly 8 percentage points. 2 That number helps set realistic expectations during prescribing counseling.

Fasting lipid panels and liver enzymes, recommended at baseline and 12 months for most post-bariatric patients, do not require modification because of bremelanotide. The drug has no known hepatotoxic or dyslipidemic effects. 1